Cargando…

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with a poor prognosis. Pirfenidone is the first antifibrotic agent to be approved for IPF-treatment as it is able to slow down disease progression. However, there is no curative treatment other than lung transplantation. B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korfei, Martina, Stelmaszek, Daniel, MacKenzie, BreAnne, Skwarna, Sylwia, Chillappagari, Shashipavan, Bach, Anna C., Ruppert, Clemens, Saito, Shigeki, Mahavadi, Poornima, Klepetko, Walter, Fink, Ludger, Seeger, Werner, Lasky, Joseph A., Pullamsetti, Soni S., Krämer, Oliver H., Guenther, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258535/ https://www.ncbi.nlm.nih.gov/pubmed/30481203 http://dx.doi.org/10.1371/journal.pone.0207915

Ejemplares similares

Exhalative Breath Markers Do Not Offer for Diagnosis of Interstitial Lung Diseases: Data from the European IPF Registry (eurIPFreg) and Biobank
por: Krauss, Ekaterina, et al.
Publicado: (2019)

Therapeutic induction of Bcl2‐associated athanogene 3‐mediated autophagy in idiopathic pulmonary fibrosis
por: Chillappagari, Shashipavan, et al.
Publicado: (2022)

Evaluation of Regional Pulmonary Ventilation in Spontaneously Breathing Patients with Idiopathic Pulmonary Fibrosis (IPF) Employing Electrical Impedance Tomography (EIT): A Pilot Study from the European IPF Registry (eurIPFreg)
por: Krauss, Ekaterina, et al.
Publicado: (2021)

Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
por: Korfei, Martina, et al.
Publicado: (2022)

Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
por: Vu, Tuong N., et al.
Publicado: (2019)

Regulation of macroautophagy in amiodarone‐induced pulmonary fibrosis
por: Mahavadi, Poornima, et al.
Publicado: (2015)

Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg)
por: Krauss, Ekaterina, et al.
Publicado: (2020)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
por: Finnerty, James Patrick, et al.
Publicado: (2021)

PACS2–TRPV1 axis is required for ER–mitochondrial tethering during ER stress and lung fibrosis
por: Knoell, Jessica, et al.
Publicado: (2022)

Regulation and role of the ER stress transcription factor CHOP in alveolar epithelial type-II cells
por: Klymenko, Oleksiy, et al.
Publicado: (2019)

Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
por: Krauss, Ekaterina, et al.
Publicado: (2020)

Antifibrotic Effects of Caffeine, Curcumin and Pirfenidone in Primary Human Keratocytes
por: Talpan, Delia, et al.
Publicado: (2023)

The ageing lung under stress
por: Korfei, Martina, et al.
Publicado: (2020)

Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis
por: Komiya, Chikara, et al.
Publicado: (2017)

Pirfenidone improves survival in IPF: results from a real-life study
por: Margaritopoulos, George A., et al.
Publicado: (2018)

Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience
por: Levra, Stefano, et al.
Publicado: (2022)

The antifibrotic drug pirfenidone inhibits spondyloarthritis fibroblast-like synoviocytes and osteoblasts in vitro
por: Stougaard, Julie, et al.
Publicado: (2018)

Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy
por: d’Alessandro, Miriana, et al.
Publicado: (2021)

IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe
por: Duck, Annette, et al.
Publicado: (2015)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
por: Torrisi, Sebastiano Emanuele, et al.
Publicado: (2019)

Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management
por: Wells, Athol U.
Publicado: (2022)

Pharmacological basis of the antifibrotic effects of pirfenidone: Mechanistic insights from cardiac in-vitro and in-vivo models
por: Sartiani, Laura, et al.
Publicado: (2022)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study
por: Kang, Jieun, et al.
Publicado: (2023)

Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis
por: MacKenzie, BreAnne, et al.
Publicado: (2015)

SIAH ubiquitin E3 ligases as modulators of inflammatory gene expression
por: Schmitz, M. Lienhard, et al.
Publicado: (2022)

Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction
por: Chillappagari, Shashi, et al.
Publicado: (2015)

Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
por: Biondini, Davide, et al.
Publicado: (2021)

Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis
por: Ebrahimpour, Afshin, et al.
Publicado: (2022)

Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients
por: Bondue, Benjamin, et al.
Publicado: (2019)

SIAH2-mediated and organ-specific restriction of HO-1 expression by a dual mechanism
por: Chillappagari, Shashipavan, et al.
Publicado: (2020)

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
por: Guenther, Andreas, et al.
Publicado: (2018)

Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
por: Krauss, Ekaterina, et al.
Publicado: (2019)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients
por: Fois, Alessandro Giuseppe, et al.
Publicado: (2018)

Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry
por: Zurkova, Monika, et al.
Publicado: (2019)

Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study
por: Lee, Eung Gu, et al.
Publicado: (2021)

Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
por: Kolonics-Farkas, Abigél M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nc6jf1scefo47c5hkdei3dbfpc